Abvc Biopharma (ABVC) Short term Debt (2016 - 2026)
Abvc Biopharma's (ABVC) quarterly Short term Debt came in at $88737.0 in Q1 2026, down 88.93% YoY from $801407.0 in Q1 2025, and down 88.25% on a QoQ basis from $755512.0 in Q4 2025.
Abvc Biopharma (ABVC) Short term Debt (2016 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 10 years of Short term Debt data on file, last reported at $88737.0 in Q1 2026.
- Quarterly Short term Debt fell 88.93% year-over-year to $88737.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88737.0 (down 88.93% YoY) and the FY2025 annual result came in at $755512.0, down 10.09% from the prior year.
- Short term Debt retreated to $88737.0 in Q1 2026, from $755512.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $1.9 million in Q4 2022 to a low of $88737.0 in Q1 2026.
- A 5-year average of $785086.5 and a median of $840252.0 in 2024 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2022 — Short term Debt surged 381.35% — and 2026, when it tumbled 88.93%.
- Tracing ABVC's Short term Debt over 5 years: stood at $1.9 million in 2022, then slumped by 52.51% to $899250.0 in 2023, then slipped by 6.56% to $840252.0 in 2024, then fell by 10.09% to $755512.0 in 2025, then tumbled by 88.25% to $88737.0 in 2026.
- The last three Short term Debt figures came in at $88737.0 (Q1 2026), $755512.0 (Q4 2025), and $809103.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59,462.00 |
| Mar 31, 2026 | 88,737.00 |
| Dec 31, 2025 | 755,512.00 |
| Sep 30, 2025 | 809,103.00 |
| Jun 30, 2025 | 871,951.00 |
| Mar 31, 2025 | 801,407.00 |
| Dec 31, 2024 | 840,252.00 |
| Sep 30, 2024 | 896,250.00 |
| Jun 30, 2024 | 847,000.00 |
| Mar 31, 2024 | 860,750.00 |
| Dec 31, 2023 | 899,250.00 |
| Sep 30, 2023 | 852,500.00 |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 451,826.00 |
| Jun 30, 2022 | 461,612.00 |
| Mar 31, 2022 | 446,397.00 |
| Dec 31, 2021 | 393,424.00 |
| Sep 30, 2021 | 298,269.00 |
| Jun 30, 2021 | 1.64 Mn |
| Mar 31, 2021 | 1.62 Mn |